Tonix Pharmaceuticals has undertaken several strategic initiatives, including the repayment of a mortgage with JGB Capital, making the company debt-free. The company also repurchased 250,000 shares of its common stock under the 2024 share repurchase program. Additionally, Tonix entered into an artificial intelligence and machine learning drug discovery collaboration with X-Chem, Inc. to accelerate the development of small molecules as orally available host-targeted broad-spectrum medical countermeasures.